BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23414744)

  • 1. Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors.
    Conti E; Romiti A; Musumeci MB; Passerini J; Zezza L; Mastromarino V; D'Antonio C; Marchetti P; Paneni F; Autore C; Volpe M
    Int J Cardiol; 2013 Sep; 167(6):2421-9. PubMed ID: 23414744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.
    Bonura F; Di Lisi D; Novo S; D'Alessandro N
    Cardiovasc Toxicol; 2012 Jun; 12(2):93-107. PubMed ID: 21894547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
    André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
    Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eschenhagen T; Force T; Ewer MS; de Keulenaer GW; Suter TM; Anker SD; Avkiran M; de Azambuja E; Balligand JL; Brutsaert DL; Condorelli G; Hansen A; Heymans S; Hill JA; Hirsch E; Hilfiker-Kleiner D; Janssens S; de Jong S; Neubauer G; Pieske B; Ponikowski P; Pirmohamed M; Rauchhaus M; Sawyer D; Sugden PH; Wojta J; Zannad F; Shah AM
    Eur J Heart Fail; 2011 Jan; 13(1):1-10. PubMed ID: 21169385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
    Baker WL; White CM
    Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
    Pereg D; Lishner M
    Eur Heart J; 2008 Oct; 29(19):2325-6. PubMed ID: 18762551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac toxicity from systemic cancer therapy: a comprehensive review.
    Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A
    Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
    Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prevalence of cardiovascular risk factors in patients with acute coronary syndrome and indications for treatment with oral anticoagulation.
    Owsiak M; Pelc-Nowicka A; Badacz L; Dubiel J; Dudek D; Gajos G; Grodecki J; Jankowski P; Kawecka-Jaszcz K; Mirek-Bryniarska E; Nessler J; Podolec P; Sadowski J; Tracz W; Zabojszcz M; Żmudka K; Bryniarski L
    Kardiol Pol; 2011; 69(9):907-12. PubMed ID: 21928197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies.
    Lefebvre CW; Hoekstra J
    Hosp Pract (1995); 2010 Apr; 38(2):40-9. PubMed ID: 20469612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
    Sinhal AR; Aylward PE
    Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
    Armani AM
    Crit Pathw Cardiol; 2010 Dec; 9(4):199-202. PubMed ID: 21119337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.